Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

8W5C

Crystal structure of FGFR4 kinase domain in complex with 8K

Summary for 8W5C
Entry DOI10.2210/pdb8w5c/pdb
DescriptorFibroblast growth factor receptor 4, N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-5-methanoyl-6-[(4-methylpiperazin-1-yl)methyl]-1-propan-2-yl-pyrrolo[3,2-b]pyridine-3-carboxamide (3 entities in total)
Functional Keywordstransferase-inhibitor complex, transferase
Biological sourceHomo sapiens (human)
Total number of polymer chains2
Total formula weight68383.00
Authors
Zhang, Z.M.,Huang, H.S. (deposition date: 2023-08-26, release date: 2024-07-31)
Primary citationYang, F.,Lin, Q.,Song, X.,Huang, H.,Chen, X.,Tan, J.,Li, Y.,Zhou, Y.,Tu, Z.,Du, H.,Zhang, Z.M.,Ortega, R.,Lin, X.,Patterson, A.V.,Smaill, J.B.,Chen, Y.,Lu, X.
Discovery of 6-Formylpyridyl Urea Derivatives as Potent Reversible-Covalent Fibroblast Growth Factor Receptor 4 Inhibitors with Improved Anti-Hepatocellular Carcinoma Activity.
J.Med.Chem., 67:2667-2689, 2024
Cited by
PubMed Abstract: Fibroblast growth factor receptor 4 (FGFR4) has been considered as a potential anticancer target due to FGF19/FGFR4 mediated aberrant signaling in hepatocellular carcinoma (HCC). Several FGFR4 inhibitors have been reported, but none have gained approval. Herein, a series of 5-formyl-pyrrolo[3,2-]pyridine-3-carboxamides and a series of 6-formylpyridyl ureas were characterized as selective reversible-covalent FGFR4 inhibitors. The representative 6-formylpyridyl urea exhibited excellent potency against FGFR4, FGFR4, and FGFR4 with IC values of 16.3, 12.6, and 57.3 nM, respectively. It also potently suppressed proliferation of Ba/F3 cells driven by FGFR4, FGFR4, and FGFR4, and FGFR4-dependent Hep3B and Huh7 HCC cells, with IC values of 1.2, 13.5, 64.5, 15.0, and 20.4 nM, respectively. Furthermore, displayed desirable microsomal stability and significant in vivo efficacy in the Huh7 HCC cancer xenograft model in nude mice. The study provides a promising new lead for anticancer drug discovery directed toward overcoming FGFR4 gatekeeper mutation mediated resistance in HCC patients.
PubMed: 38348819
DOI: 10.1021/acs.jmedchem.3c01810
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.3 Å)
Structure validation

227344

PDB entries from 2024-11-13

PDB statisticsPDBj update infoContact PDBjnumon